TSAO-T

Cat. No.: HY-15354: Data Sheet Handling Instructions
FAQs
Technical Support

TSAO-T is a HIV-1 reverse transcriptase inhibitor. TSAO-T can be used in the research of HIV infection.

For research use only. We do not sell to patients.

TSAO-T Chemical Structure

CAS No. : 141781-17-1

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All HIV Isoform Specific Products:

View All Isoforms

HIV HIV-1 HIV-2

Biological Activity
Purity & Documentation
References
Customer Review

Description

TSAO-T is a HIV-1 reverse transcriptase inhibitor. TSAO-T can be used in the research of HIV infection^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
CCRF-CEM	CC₅₀	12 μM Compound: TSAO-T	Cytotoxicity against human CEM cells after 4 days Cytotoxicity against human CEM cells after 4 days	[PMID: 21880398]
CCRF-CEM	CC₅₀	16 μM Compound: TSAO-T	Concentration of compound required to reduce by 50% the number of viable cells in mock infected CEM cell cultures Concentration of compound required to reduce by 50% the number of viable cells in mock infected CEM cell cultures	[PMID: 15974581]
CCRF-CEM	CC₅₀	16 μM Compound: TSAO-T	Cytotoxicity against mock-infected human CEM cells assessed as reduction of cell viability after 4 days Cytotoxicity against mock-infected human CEM cells assessed as reduction of cell viability after 4 days	[PMID: 18316194]
CCRF-CEM	CC₅₀	16 μM Compound: TSAO-T	Cytotoxicity against human CEM cells Cytotoxicity against human CEM cells	[PMID: 18353641]
CCRF-CEM	EC₅₀	0.01 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase E138D mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase E138D mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	0.03 μg/mL Compound: 7, TSAO-T	Antiviral activity against wild type HIV1 3B infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against wild type HIV1 3B infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	0.06 μM Compound: 7, TSAO-T	Antiviral activity against wild type HIV1 infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against wild type HIV1 infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	0.06 μM Compound: TSAO-T	Concentration of compound required to inhibit HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50% Concentration of compound required to inhibit HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50%	[PMID: 15974581]
CCRF-CEM	EC₅₀	0.06 μM Compound: TSAO-T	Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 18316194]
CCRF-CEM	EC₅₀	0.06 μM Compound: TSAO-T	Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of viral replication Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of viral replication	[PMID: 18353641]
CCRF-CEM	EC₅₀	0.06 μM Compound: TSAO-T	Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days	[PMID: 21880398]
CCRF-CEM	EC₅₀	0.07 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	0.22 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase V179N mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase V179N mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	0.23 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	0.4 μM Compound: TSAO-T	Concentration of compound inhibiting Lys103-Asn mutant HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50% Concentration of compound inhibiting Lys103-Asn mutant HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50%	[PMID: 15974581]
CCRF-CEM	EC₅₀	1.9 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase V106A mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase V106A mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	2 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	3 μM Compound: TSAO-T	Concentration of compound inhibiting Tyr181- Cys mutant HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50% Concentration of compound inhibiting Tyr181- Cys mutant HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50%	[PMID: 15974581]
CCRF-CEM	EC₅₀	4.6 μM Compound: TSAO-T	Concentration of compound inhibiting Glu138-Lys mutant HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50% Concentration of compound inhibiting Glu138-Lys mutant HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50%	[PMID: 15974581]
CCRF-CEM	EC₅₀	> 10 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase G190E mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase G190E mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	> 10 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase Y181I mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase Y181I mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	> 10 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	> 20 μM Compound: 7, TSAO-T	Antiviral activity against wild type HIV2 infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against wild type HIV2 infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	> 20 μM Compound: TSAO-T	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days	[PMID: 21880398]
CCRF-CEM	EC₅₀	> 3.3 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase Y188H mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase Y188H mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	> 3 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	> 4 μM Compound: TSAO-T	Concentration of compound required to inhibit HIV-2 (ROD) induced cytopathicity in CEM cell culture by 50% Concentration of compound required to inhibit HIV-2 (ROD) induced cytopathicity in CEM cell culture by 50%	[PMID: 15974581]
CCRF-CEM	EC₅₀	> 4 μM Compound: TSAO-T	Antiviral activity against HIV2 ROD in CEM cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against HIV2 ROD in CEM cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 18316194]
CCRF-CEM	EC₅₀	> 50 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase N136A/Q/K mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase N136A/Q/K mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
Huh-7	CC₅₀	> 100 μM Compound: TSAO-T	Cytotoxicity against human HuH7 cells after 72 hrs Cytotoxicity against human HuH7 cells after 72 hrs	[PMID: 21880398]
Huh-7	EC₅₀	14 μM Compound: TSAO-T	Antiviral activity against HCV2a JFH1 infected in human Huh7 cells assessed as inhibition of viral replication after 72 hrs by luciferase reporter gene assay Antiviral activity against HCV2a JFH1 infected in human Huh7 cells assessed as inhibition of viral replication after 72 hrs by luciferase reporter gene assay	[PMID: 21880398]
Lymphocyte	EC₅₀	0.034 μg/mL Compound: 12a	Concentration required to inhibit HIV-1 induced cytopathicity in human MT-4 lymphocyte cells. Concentration required to inhibit HIV-1 induced cytopathicity in human MT-4 lymphocyte cells.	[PMID: 1495006]
MT4	CC₅₀	14 μM Compound: TSAO-T	Concentration of compound required to reduce by 50% the number of viable cells in mock infected MT-4 cell cultures Concentration of compound required to reduce by 50% the number of viable cells in mock infected MT-4 cell cultures	[PMID: 15974581]
MT4	CC₅₀	14 μM Compound: TSAO-T	Inhibition of MT4 cell viability Inhibition of MT4 cell viability	[PMID: 16884295]
MT4	CC₅₀	7.7 μg/mL Compound: 12a	Concentration required to reduce human MT-4 cell viability by 50%. Concentration required to reduce human MT-4 cell viability by 50%.	[PMID: 1495006]
MT4	EC₅₀	0.06 μM Compound: TSAO-T	Concentration of compound required to inhibit HIV-1(IIIB) induced cytopathicity in MT-4 cell culture by 50% Concentration of compound required to inhibit HIV-1(IIIB) induced cytopathicity in MT-4 cell culture by 50%	[PMID: 15974581]
MT4	EC₅₀	0.06 μM Compound: TSAO-T	Antiviral activity against HIV1 in MT4 cells Antiviral activity against HIV1 in MT4 cells	[PMID: 16884295]
MT4	EC₅₀	> 20 μM Compound: TSAO-T	Concentration of compound required to inhibit HIV-2 (ROD) induced cytopathicity in MT-4 cell culture by 50% Concentration of compound required to inhibit HIV-2 (ROD) induced cytopathicity in MT-4 cell culture by 50%	[PMID: 15974581]

Molecular Weight

589.85

Formula

C₂₄H₄₃N₃O₈SSi₂

CAS No.

141781-17-1

SMILES

O=C1NC(C(C)=CN1[C@@H]([C@@H]2O[Si](C)(C(C)(C)C)C)O[C@H](CO[Si](C)(C(C)(C)C)C)[C@@]32C(N)=CS(O3)(=O)=O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Bonache MC, et al. Improving the antiviral efficacy and selectivity of HIV-1 reverse transcriptase inhibitor TSAO-T by the introduction of functional groups at the N-3 position. J Med Chem. 2005 Oct 20;48(21):6653-60. [Content Brief]

TSAO-T Related Classifications

Infection

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

TSAO-T141781-17-1Reverse TranscriptaseHIVHuman immunodeficiency virusHIV-1HIV-2Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

TSAO-T

TSAO-T Related Antibodies

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All HIV Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

TSAO-T Related Classifications

Molarity Calculator

Dilution Calculator